Identification and analysis of the reactive metabolites related to the hepatotoxicity of safrole

References

• Baillie TA, Davis MR. (1993). Mass spectrometry in the analysis of glutathione conjugate. Biol Mass Spectrom 22:319–25.
   PubMedGoogle Scholar
• Benedetti MS, Malnoë A, Broillet AL. (1977). Absorption, metabolism and excretion of safrole in the rat and man. Toxicology 7:69–83.
   PubMed Web of Science ®Google Scholar
• Bertelsen KM, Venkatakrishnan K, Von Moltke LL, et al. (2003). Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine. Drug Metab Dispos 31:289–93.
   PubMed Web of Science ®Google Scholar
• Bolton JL, Acay NM, Vukomanovic V. (1994). Evidence that 4-allyl-o-quinones spontaneously rearrange to their more electrophilic quinone methides: potential bioactivation mechanism for the hepatocarcinogen safrole. Chem Res Toxicol 7:443–50.
   PubMed Web of Science ®Google Scholar
• Bolton JL, Trush MA, Penning TM, et al. (2000). Role of quinones in toxicology. Chem Res Toxicol 13:135–60.
   PubMed Web of Science ®Google Scholar
• Borchert P, Miller JA, Miller EC, et al. (1973a). 1′-Hydroxysafrole, a proximate carcinogenic metabolite of safrole in the rat and mouse. Cancer Res 33:590–600.
   PubMed Web of Science ®Google Scholar
• Borchert P, Wislocki PG, Miller JA, et al. (1973b). The metabolism of the naturally occurring hepatocarcinogen safrole to 1′-hydroxysafrole and the electrophilic reactivity of 1′-acetoxysafrolel. Cancer Res 33:575–89.
   PubMed Web of Science ®Google Scholar
• Chatterjee P, Franklin MR. (2003). Human cytochrome p450 inhibition and metabolic-intermediate complex formation by goldenseal extract and its methylenedioxyphenyl components. Drug Metab Dispos 31:1391–7.
   PubMed Web of Science ®Google Scholar
• Chiang SY, Lee PY, Lai MT, et al. (2011). Safrole-2′,3′-oxide induces cytotoxic and genotoxic effects in HepG2 cells and in mice. Mutat Res 726:234–41.
   PubMed Web of Science ®Google Scholar
• Chung YT, Chen CL, Wu CC, et al. (2008). Safrole-DNA adduct in hepatocellular carcinoma associated with betel quid chewing. Toxicol Lett 183:21–7.
   PubMed Web of Science ®Google Scholar
• Fang ZZ, Krausz KW, Li F, et al. (2012). Metabolic map and bioactivation of the anti-tumour drug noscapine. Br J Pharmacol 167:1271–86.
   PubMed Web of Science ®Google Scholar
• Fontana E, Dansette PM, Poli SM. (2005). Cytochrome P450 enzymes mechanism based inhibitors: common sub-structures and reactivity. Curr Drug Metab 6:413–54.
   PubMed Web of Science ®Google Scholar
• Halpert JR. (1995). Structural basis of selective cytochrome P450 inhibition. Annu Rev Pharmacol Toxicol 35:29–53.
   PubMed Web of Science ®Google Scholar
• He LN, Yang AH, Cui TY, et al. (2015). Reactive metabolite activation by CYP2C19-mediated rhein hepatotoxicity. Xenobiotica 45:361–72.
   PubMed Web of Science ®Google Scholar
• Hodgson E, Philpot RM. (1975). Interaction of methylenedioxyphenyl (1,3-benzodioxole) compounds with enzymes and their effects on mammals. Drug Metab Rev 3:231–301.
   Web of Science ®Google Scholar
• Hollenberg PF, Kent UM, Bumpus NN. (2008). Mechanism-based inactivation of human cytochromes p450s: experimental characterization, reactive intermediates, and clinical implications. Chem Res Toxicol 21:189–205.
   PubMed Web of Science ®Google Scholar
• Ioannides C, Delaforge M, Parke DV. (1981). Safrole: its metabolism, carcinogenicity and interactions with cytochrome p-450. Food Cosmet Toxicol 19:657–66.
   PubMedGoogle Scholar
• Jurd L, Fye RL, Morgan J. Jr (1979). New types of insect chemosterilants. Benzylphenols and benzyl-1,3-benzodioxole derivatives as additives to housefly diet. Food Chem 27:1007–16.
   Web of Science ®Google Scholar
• Kent UM, Juschyshyn MI, Hollenberg PF. (2001). Mechanism-based inactivators as probes of cytochrome P450 structure and function. Curr Drug Metab 2:215–43.
   PubMed Web of Science ®Google Scholar
• Lee JY, Lee SY, Oh SJ, et al. (2012). Assessment of drug-drug interactions caused by metabolism-dependent cytochrome P450 inhibition. Chem Biol Interact 198:49–56.
   PubMed Web of Science ®Google Scholar
• Luo G, Guenthner TM. (1996). Covalent binding to DNA in vitro of 2′,3′-oxides derived from allylbenzene analogs. Drug Metab Dispos 24:1020–7.
   PubMed Web of Science ®Google Scholar
• Ma B, Prueksaritanont T, Lin JH. (2000). Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos 28:125–30.
   PubMed Web of Science ®Google Scholar
• Martati E, Boersma MG, Spenkelink A, et al. (2012). Physiologically based biokinetic (PBBK) modeling of safrole bioactivation and detoxification in humans as compared with rats. Toxicol Sci 128:301–16.
   PubMed Web of Science ®Google Scholar
• Masubuchi Y, Horie T. (2007). Toxicological significance of mechanism-based inactivation of cytochrome P450 enzymes by drugs. Crit Rev Toxicol 37:389–412.
   PubMed Web of Science ®Google Scholar
• Monks TJ, Jones DC, Bai F, et al. (1992). Toxicology of quinone-thioethers. Crit Rev Toxicol 26:132–6.
   Google Scholar
• Murray M, Wilkinson CF, Dube CE. (1985). Induction of rat-hepatic microsomal cytochrome P-450 and aryl hydrocarbon hydroxylase by 1,3-benzodioxole derivatives. Xenobiotica 15:361–8.
   PubMed Web of Science ®Google Scholar
• Nakayama S, Takakusa H, Watanabe A, et al. (2011). Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites. Drug Metab Dispos 39:1247–54.
   PubMed Web of Science ®Google Scholar
• Pershing LK, Franklin MR. (1982). Cytochrome P-450 metabolic-intermediate complex formation and induction by macrolide antibiotics: a new class of agents. Xenobiotica 12:687–99.
   PubMed Web of Science ®Google Scholar
• Peterson LA, Cummings ME, Vu CC, et al. (2005). Glutathione trapping to measure microsomal oxidation of furan to cis-2-butene-1,4-dial. Drug Metab Dispos 33:1453–8.
   PubMed Web of Science ®Google Scholar
• Shebley M, Kent UM, Ballou DP, et al. (2009). Mechanistic analysis of the inactivation of cytochrome P450 2B6 by phencyclidine: effects on substrate binding, electron transfer, and uncoupling. Drug Metab Dispos 37:745–52.
   PubMed Web of Science ®Google Scholar
• Shen LC, Chiang SY, Lin MH, et al. (2012). In vivo formation of N7-guanine DNA adduct by safrole 2′,3′-oxide in mice. Toxicol Lett 213:309–15.
   PubMed Web of Science ®Google Scholar
• Silverman RB. (1988). Mechanism-based enzyme inactivation: chemistry and enzymology. Boca Raton, FL: CRC Press
   Google Scholar
• Silverman RB. (1995). Mechanism-based enzyme inactivators. Meth Enzymol 249:240–83.
   PubMed Web of Science ®Google Scholar
• Sugumaran M, Bolton J. (1995). Direct evidence for quinone-quinone methide tautomerism during tyrosinase catalyzed oxidation of 4-allylcatechol. Biochem Biophys Res Commun 213:469–74.
   PubMed Web of Science ®Google Scholar
• Ueng YF, Hsieh CH, Don MJ, et al. (2004). Identification of the main human cytochrome P450 enzymes involved in safrole 1′-hydroxylation. Chem Res Toxicol 17:1151–6.
   PubMed Web of Science ®Google Scholar
• Ueng YF, Hsieh CH, Don MJ. (2005). Inhibition of human cytochrome P450 enzymes by the natural hepatotoxin safrole. Food Chem Toxicol 43:707–12.
   PubMed Web of Science ®Google Scholar
• Wang YH, Jones DR, Hall SD. (2004). Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos 32:259–66.
   PubMed Web of Science ®Google Scholar
• Wislocki PG, Borchert P, Miller JA, et al. (1976). The metabolic activation of the carcinogen 1′-hydroxysafrole in vivo and in vitro and the electrophilic reactivities of possible ultimate carcinogens. Cancer Res 36:1686–95.
   PubMed Web of Science ®Google Scholar
• Wislocki PG, Miller EC, Miller JA, et al. (1977). Carcinogenic and mutagenic activities of safrole, 1′-hydroxysafrole, and some known or possible metabolites. Cancer Res 37:1883–91.
   PubMed Web of Science ®Google Scholar
• Xie C, Zhong D, Chen X. (2013). A fragmentation-based method for the differentiation of glutathione conjugates by high-resolution mass spectrometry with electrospray ionization. Anal Chim Acta 788:89–98.
   PubMed Web of Science ®Google Scholar
• Yang AH, He X, Chen JX, et al. (2015). Identification and characterization of reactive metabolites in myristicin-mediated mechanism-based inhibition of CYP1A2. Chem Biol Interact 237:133–40.
   PubMed Web of Science ®Google Scholar
• Yu FS, Huang AC, Yang JS, et al. (2011). Safrole induces cell death in human tongue squamous cancer SCC-4 cells through mitochondria-dependent caspase activation cascade apoptotic signaling pathways. Environ Toxicol 27:433–44.
   PubMed Web of Science ®Google Scholar
• Zhang FL, He X, Zhai YR, et al. (2015). Mechanism-based inhibition of CYPs and RMs-induced hepatoxicity by rutaecarpine. Xenobiotica 45:978–89.
   PubMed Web of Science ®Google Scholar
• Zhang W, Zhang J, Zhang M, Nie L. (2014). Protective effect of Asarum extract in rats with adjuvant arthritis. Exp Ther Med 8:1638–42.
   PubMed Web of Science ®Google Scholar
• Zhou S, Chan E, Lim LY, Boelsterli UA. (2004). Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4. Curr Drug Metab 5:415–42.
   PubMed Web of Science ®Google Scholar
• Zhou S, Yung CS, Cher GB, et al. (2005). Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet 44:279–304.
   PubMed Web of Science ®Google Scholar